Discover the innovative and unique antibiotic development platform developed by Obulytix
Total raised: $4.32M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.12.2023 | Seed | $4.32M | - |
Mentions in press and media 1
| Date | Title | Description |
| 06.12.2023 | Obulytix raises € 4 million round in Seed funding | Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. The innovative, phage lysin-based platform – leveraging the power of artificial i... |